MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/200/0.1/20.09.24 | Real-time Bid/Ask 10:59:22 2024-06-10 am EDT | ||
| 0.056 EUR / 0.062 EUR | +1.72% |
|
| Current month | +48.72% | ||
| 1 month | +26.09% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-10 | 0.033 | -43.10% |
| 24-06-07 | 0.058 | -12.12% |
| 24-06-06 | 0.066 | +17.86% |
| 24-06-05 | 0.056 | +21.74% |
| 24-06-04 | 0.046 | +15.00% |
Delayed Quote Börse Stuttgart
Last update June 10, 2024 at 07:54 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | ME8N0C |
| ISIN | DE000ME8N0C4 |
| Date issued | 2024-02-13 |
| Strike | 200 $ |
| Maturity | 2024-09-20 (102 Days) |
| Parity | 10 : 1 |
| Emission price | 0.08 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.189 € |
|---|---|
| Lowest since issue | 0.019 € |
| Spread | 0.006 € |
| Spread % | 9.52% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
984
DKK
Average target price
920.8
DKK
Spread / Average Target
-6.43%
- Stock Market
- Warrants
- Warrant
